Panakeia to attend and present at upcoming scientific and business conferences
- Stella Lempidaki
- Sep 5
- 2 min read
Cambridge, UK, 5 September 2025 – Panakeia (“the Company”), a pioneer in AI-enabled multi-omic biomarker profiling, is pleased to confirm that it will be attending and presenting at a number of conferences in September 2025.
37th European Congress of Pathology - September 6-10, Vienna, Austria
Poster presentation “Evaluating the performance and generalisability of a clinical-grade AI-based approach for determining MSI/MMR status from H&E-stained colorectal cancer slides: A blinded multi-regional study”
Poster Session: PS-02 Digital and Computational Pathology
Poster number: 006
Date and time: September 7, 09:30 – 10:30 CEST
World Clinical Biomarkers & CDx Summit - September 22-25, Boston, Massachusetts, US
Chairing a panel discussion titled “H&E-Based Molecular Profiling: From Bench to Bedside in the Era of Precision Medicine & AI”
Date and time: September 24, 12.10pm EST
Digital Diagnostics Summit - September 28-30, Park City, Utah, US
If you would like to meet with the Panakeia team in any of the above conferences, please get in touch via the contact form on our website.
About Panakeia
Panakeia is a pioneer in AI-enabled molecular profiling. The Company’s AI-driven software provides comprehensive multi-omic information (DNA, RNA, protein, metabolite changes) directly from routinely used images of tissues and cells in minutes instead of days or weeks. The software enables same-day treatment decision-making in the clinic and fast-tracks drug development for biopharma without the need for time and resource intensive laboratory tests.
Panakeia’s PANProfiler platform is available as a research use tool for patient screening in clinical trials. The Company’s two clinical products for breast and colon cancers are built using the PANProfiler platform. These products are approved and clinically deployed in the UK with several more products in the pipeline.
Headquartered in Cambridge, UK, Panakeia is focused on improving the speed and accuracy of pathology examinations for all patients.
To learn more about Panakeia’s platform visit: https://www.panakeia.ai/
For more information please contact:
Stella Lempidaki, PhD
Head of Communications